#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Finger on the Pulse of the Times with Automated Peritoneal Dialysis and Remote Patient Monitoring

The method of peritoneal dialysis brings many advantages to patients with chronic kidney disease and significantly eases their lives. Peritoneal dialysis saves time for both the patients themselves and the attending healthcare personnel. Modern medicine now offers an innovative tool that can remotely monitor the patient's condition, with the possibility of adjusting the treatment regimen.
Source: Chronic Kidney Disease 29. 9. 2020

News Addition of ixazomib to lenalidomide and dexamethasone in multiple myeloma − Data from real-world Czech practice

A group of Czech and Slovak experts led by Associate Professor Jiří Minařík from the Hemato-Oncology Clinic of the Faculty of Medicine UP and University Hospital Olomouc published the final results of an observational study evaluating the addition of ixazomib to the combination with lenalidomide and dexamethasone in patients with relapsing/refractory multiple myeloma (RRMM). This involves experiences from real clinical practice, with data obtained from the Czech Registry of Monoclonal Gammopathies.
Source: Hematologic Malignancies 22. 12. 2022

News Effect of Combination of Dorzolamide with Timolol for Wet Age-Related Macular Degeneration

In some eyes with wet age-related macular degeneration (AMD), exudation does not stop despite frequent intravitreal injections of vascular endothelial factor blockers (anti-VEGF). Adjuvant therapy that reduces edema may improve overall treatment outcomes concerning visual functions. A recently published multicenter randomized clinical study evaluated the effect of local therapy combining dorzolamide and timolol in patients with this issue.
Source: Glaucoma 3. 7. 2020

News Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors

Activated prothrombin complex concentrates (aPCC) are essential drugs that not only allow the control of bleeding in patients with congenital hemophilia A and inhibitors but also help to prevent such bleeding. A recent review article by experts from several European institutions provides an up-to-date view of the development, challenges, and future directions in the use of aPCC in the treatment of hemophilia.
Source: Hemophilia 2. 11. 2020

News Pharmacokinetics and Safety Profile of Bilastine in Patients Aged 6–11 Years – Findings from Post-hoc Analysis of Studies

The second-generation antihistamine bilastine is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria in children over 6 years old. Post-hoc analyses of two clinical studies focused on its safety profile and pharmacokinetics in the pediatric population.
Source: Allergic Reactions 4. 3. 2020

News How Does Empagliflozin Stand in Terms of Diabetic Retinopathy Risk? We Have Answers Not Only from Controlled Studies but Also from Real Practice

Modern antidiabetics – gliflozins and glucagon-like peptide-1 receptor agonists (GLP-1RA) – significantly help improve the management of type 2 diabetes (DM2). In addition to reliable glycemic control, they offer other benefits. For example, gliflozins are known for their cardio- and renoprotective properties. GLP-1RA also reduce cardiovascular (CV) risk, though clinical evaluation (SUSTAIN-6) suggests a possible higher risk of retinopathy. This is also being investigated with gliflozins. How empagliflozin fares in this respect has been shown by the prospective randomized EMPA-REG OUTCOME study and the real-world EMPRISE evaluation.
Source: Diabetes 5. 12. 2023

News Good news for sleep in patients with axial spondyloarthritis – ixekizumab effectively reduces night-time back pain

The targeted treatment of axial spondyloarthritis currently relies on the anti-inflammatory effects of tumor necrosis factor (TNF) inhibitors, interleukin IL-17 inhibitors, and Janus kinase (JAK) inhibitors. Besides the objective efficacy of these targeted treatments, it is crucial to describe their influence on subjective symptoms for decision-making in clinical practice. The evaluation of the analgesic effect of ixekizumab (IXE) was provided by the randomized controlled trial COAST-V.
Source: Biological Treatment 14. 11. 2022

Journal articles Promising treatment modalities in the therapy of myelodysplastic syndromes

Author of the article: A. Jonášová Source: Klinická onkologie | 5/2021 18. 10. 2021

News Efficacy of Luspatercept in 1st Line Treatment of Anemia Due to Low-Risk Myelodysplastic Syndrome

A planned interim analysis of the COMMANDS study showed a greater benefit of the innovative treatment with luspatercept compared to the established treatment with epoetin alfa in patients with anemia due to low-risk myelodysplastic syndrome (MDS) and untreated with erythropoiesis-stimulating agents (ESA). The results were published in June 2023 in the journal Lancet.
Source: Myelodysplastic Syndrome (MDS) 24. 5. 2024

News ESC 2022: Evidence of SGLT2i Effectiveness in HFrEF Treatment is Growing: How to Integrate Them into Routine Practice?

Although the need for pharmacotherapeutic options for patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is essential, challenges in implementing this medication according to guidelines persist. This issue was also discussed at a symposium held as part of this year's European Society of Cardiology Congress (ESC 2022).
Source: Heart Failure 1. 11. 2022

Journal articles Prevention of the invasion of malignant cells of gynecologic tumors during surgery

Author of the article: J. Kobilková, J. E. Jirásek, J. Jedličková, O. Benešová, J. Mašata Source: Česká gynekologie | 6/2010 20. 12. 2010

News Is Adding Fibrinogen Concentrate to Transfusion Therapy for Postpartum Hemorrhage an Effective Approach?

Significant postpartum hemorrhage can be managed with fresh frozen plasma transfusion. However, administering larger volumes is associated with several risks. The authors of the Japanese study below investigated whether fibrinogen concentrate added to fresh frozen plasma transfusions is an effective tool in reducing the need for erythrocyte concentrate and whether it helps prevent complications of intensive transfusion therapy.
Source: Life-threatening Bleeding 20. 5. 2022

News Efficacy and Safety of Levodopa/Entacapone/Carbidopa Combination in the Treatment of Advanced Parkinson's Disease – Prospective ELEGANCE Study

Therapy for advanced Parkinson's disease (PD) with a triple combination of levodopa/entacapone/carbidopa in the form of intestinal gel (LECIG) was first introduced to the Swedish market in 2018. The German team behind the ELEGANCE study aimed to gather available data and analyze the efficacy and safety of this modality in the long-term treatment of PD.
Source: Parkinson's Disease 22. 11. 2022

News Comparison of the Effect of Sonic and Manual Toothbrushes on Dental Plaque and Gingivitis Control

A clinical study on healthy volunteers with mild to moderate gingivitis compared the effectiveness of sonic and manual toothbrushes in terms of dental plaque and gingivitis occurrence. The results of the study showed that the sonic toothbrush outperformed the manual one in all observed parameters.
Source: Dental Care 16. 2. 2023

News Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population

Obesity is classified as a lifestyle disease with increasing prevalence and a rising contribution to morbidity and mortality in the general population. The epidemic of overweight and obesity also does not spare individuals with hemophilia. According to epidemiological data, the prevalence of obesity is also increasing in this population, causing a number of complications in many health aspects.
Source: Hemophilia with Movement 30. 5. 2022

News Third Generation Targeted Therapy for ROS1-Positive NSCLC

The potent third-generation tyrosine kinase inhibitor, lorlatinib, has shown activity in preclinical studies against nearly all known mutations in the ALK and ROS1 genes that lead to resistance to crizotinib treatment. Moreover, lorlatinib crosses the blood-brain barrier, offering hope for patients with CNS metastases. The results of a clinical evaluation of the efficacy and safety of lorlatinib in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) were published in The Lancet Oncology.
Source: Genetic Profile and Treatment of NSCLC 15. 4. 2020

News Contact Dermatitis in Patients with Venous Ulcers – and How to Prevent It?

The prevalence of chronic wounds increases with the rising average age, and for example, venous ulcers affect up to 2% of the global population. Materials used for wound coverage, however, present a risk for the development of contact dermatitis of allergic or irritant origin. The topic of contact dermatitis in patients with venous ulcers is covered in a review article published in the International Journal of Women’s Dermatology.
Source: Wound Healing 31. 10. 2022

News Major Orthopedic Procedures in Patients with Inhibitor Treated with Emicizumab

Italian authors presented the results of a study of a small series of hemophilia patients with inhibitors treated with emicizumab, who underwent major orthopedic surgery, at the World Federation of Hemophilia (WFH) forum. This information is very important, as emicizumab, being a new drug, offers new perspectives on how to ensure surgery for these highly risky patients.
Source: Quality Life Even with Hemophilia 28. 7. 2020

News Osimertinib in the Treatment of Patients with NSCLC with Secondary EGFR T790M Mutation – Case Study

Non-small cell lung cancer (NSCLC) is a genetically heterogeneous disease. Individualization of therapy based on the presence of specific tumor cell mutations is therefore crucial for choosing the optimal therapy for these patients. One of the targeted treatment options for patients with NSCLC with an activating mutation in the epidermal growth factor receptor (EGFR) gene is osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR TKI). We present a case study of a patient with NSCLC treated with osimertinib after disease progression due to a secondary EGFR T790M mutation resulting from afatinib therapy. The described case well illustrates the role of osimertinib in the treatment of NSCLC with secondary EGFR T790M mutation.
Source: Lung Cancer 10. 6. 2020

Journal articles Fecal microbiota transplantation – past, present, and future

Author of the article: Stebel R., Vojtilová L., Husa P. Source: Gastroenterologie a hepatologie | 1/2020 25. 2. 2020

News Can Thyroid Hormone Supplementation Reduce the Risk of Cognitive Disorders?

The recent systematic literature review presented below, published by authors from the California Institute of Behavioral Neurosciences and Psychology (CIBNP), focused, among other things, on potential associations between hypothyroidism and dementia and the impact of related therapeutic interventions in terms of improving cognitive functions.
Source: Thyroid Disorders 25. 10. 2022

Journal articles The heart transplantation

Author of the article: Lenka Špinarová, Jindřich Špinar, Jiří Vítovec Source: Vnitřní lékařství | 9/2018 15. 10. 2018

News Chemotherapy as a Risk Factor for Severe COVID-19 Course?

During the coronavirus pandemic, patients with malignant neoplastic diseases are considered an at-risk group. Whether chemotherapy is a risk factor for a more severe course of COVID-19 was the subject of the study presented below.
Source: Antiemetic Therapy 8. 4. 2021

News What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?

Recent studies indicate that target trough levels of factor 1–3% during prophylactic treatment are insufficient to fully prevent clinical and subclinical bleeding. With a sustained FVIII level > 15%, as shown in studies with mild hemophiliacs, spontaneous bleeding is very rare. This raises the question of whether achieving zero bleeding incidence with FVIII replacement therapy is possible and whether it can be a realistic goal. This topic was also explored in a presentation by Dr. Ester Zápotocká from the Clinic of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital in Prague.
Source: Hemophilia 10. 5. 2021

News Early Implementation of Highly Effective Therapy for Multiple Sclerosis

The ongoing debate about changing the approach to treating relapsing-remitting multiple sclerosis (RRMS) from an escalation strategy to the early implementation of highly effective therapy (HET) is based on the documented high inflammatory activity of the disease in its early stages and the concept of a therapeutic window for its suppression shortly after diagnosis. We bring you a summary of several recent pieces of information about the benefits and safety of HET as an initial treatment for RRMS.
Source: Neurology - Multiple Sclerosis 20. 9. 2023

1 23 24 25 26 27 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#